Kisspeptin FAQ — Essential Research Answers

Research published in the Journal of Clinical Investigation identified kisspeptin as the master regulator of GnRH (gonadotropin-releasing hormone) neurons. Without functional kisspeptin signaling, reproductive maturation and fertility cannot proceed in mammals. This discovery transformed our understanding of puberty, fertility, and metabolic-reproductive crosstalk.

We've synthesized hundreds of research-grade peptides for labs investigating reproductive endocrinology, metabolic signaling, and neuroendocrine pathways. The gap between a productive research protocol and wasted compound comes down to understanding mechanism, receptor specificity, and dosing precision. Details most product pages never address.

What is kisspeptin and how does it work in biological research?

Kisspeptin is a 54-amino-acid peptide encoded by the KISS1 gene that binds to GPR54 (also called KISS1R), a G-protein-coupled receptor expressed densely in hypothalamic GnRH neurons. Upon binding, kisspeptin triggers intracellular calcium release and activates the mitogen-activated protein kinase (MAPK) pathway, stimulating GnRH secretion. Which in turn drives luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release from the anterior pituitary. This cascade regulates gonadal steroid production, gametogenesis, and reproductive behavior across species.

Most kisspeptin FAQ resources stop at 'it regulates reproduction'. But that oversimplifies a peptide with documented roles in metabolism, energy balance, insulin secretion, and even cardiovascular tone. This kisspeptin FAQ addresses mechanism-of-action questions, structural variants (kisspeptin-10, kisspeptin-13, kisspeptin-54), receptor pharmacology, and research protocol considerations that determine experimental success. Labs working with Kisspeptin 10 need precise answers about storage, reconstitution, and dosing. Not generic peptide handling advice.

Kisspeptin Mechanism of Action and Receptor Pharmacology

Kisspeptin's biological activity is mediated entirely through GPR54, a receptor that demonstrates nanomolar affinity for kisspeptin peptides and triggers rapid downstream signaling within seconds of ligand binding. The receptor is expressed at highest density in the arcuate nucleus and anteroventral periventricular nucleus (AVPV) of the hypothalamus. Regions that integrate metabolic and reproductive signals. GPR54 knockout models in mice, rats, and humans uniformly present hypogonadotropic hypogonadism and failure to enter puberty, confirming kisspeptin-GPR54 signaling as non-redundant for reproductive axis activation.

Kisspeptin-10 (metastin 45-54), the shortest bioactive fragment, retains full agonist activity at GPR54 with EC50 values in the 1–10 nM range depending on assay conditions. The C-terminal decapeptide sequence is conserved across species and represents the minimal motif required for receptor activation. Longer isoforms. Kisspeptin-13, kisspeptin-14, and kisspeptin-54. Show similar potency but may differ in pharmacokinetics, with kisspeptin-54 exhibiting slightly longer plasma half-life due to reduced susceptibility to peptidase cleavage at the N-terminus. Research published in Endocrinology demonstrated that intravenous kisspeptin-10 in humans produces measurable LH release within 30 minutes, peaking at 60–90 minutes post-administration.

GPR54 coupling is primarily through Gαq/11, which activates phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes intracellular calcium stores, triggering GnRH vesicle exocytosis, while DAG activates protein kinase C (PKC), which potentiates the response. This rapid signaling cascade makes kisspeptin one of the most potent secretagogues for GnRH known. More potent on a molar basis than GnRH-releasing peptides used in older research models.

Our synthesis protocols for Kisspeptin 10 emphasize C-terminal sequence fidelity because even single amino acid substitutions at positions 50–54 (using kisspeptin-54 numbering) dramatically reduce receptor affinity. Every batch undergoes mass spectrometry verification to confirm exact sequence matching the bioactive fragment.

Kisspeptin Isoforms: Structural Variants and Research Applications

The KISS1 gene encodes a 145-amino-acid prepropeptide that undergoes proteolytic cleavage to generate kisspeptin-54 (the full mature peptide) and shorter fragments. Kisspeptin-14, kisspeptin-13, and kisspeptin-10. All share the same C-terminal decapeptide sequence (Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2), which constitutes the receptor-binding domain. The choice of isoform in research protocols depends on study objectives, route of administration, and pharmacokinetic considerations.

Kisspeptin-10 is the most widely used isoform in mechanistic studies because it represents the minimal bioactive sequence, simplifies synthesis quality control, and demonstrates equivalent receptor activation to longer forms in vitro. Its shorter half-life (approximately 4–6 minutes in plasma) makes it ideal for acute stimulation studies where temporal control matters. Researchers can administer kisspeptin-10 and observe GnRH/LH response within a narrow time window without prolonged systemic exposure. A 2014 study in the Journal of Neuroendocrinology used kisspeptin-10 to map dose-response curves for LH secretion in male volunteers, establishing clear pharmacodynamic relationships.

Kisspeptin-54, by contrast, shows extended plasma stability due to its longer N-terminal sequence, which sterically hinders aminopeptidase access to the bioactive C-terminus. This results in a half-life of approximately 28–30 minutes in humans. Roughly 5–6 times longer than kisspeptin-10. Protocols investigating sustained reproductive axis stimulation, chronic metabolic effects, or reproductive behavior often favor kisspeptin-54 for its prolonged bioavailability. Research in sheep models demonstrated that continuous kisspeptin-54 infusion maintains elevated LH pulse frequency for hours, whereas kisspeptin-10 requires repeated bolus dosing to sustain the same effect.

Kisspeptin-13 occupies an intermediate position. Long enough to show modest peptidase resistance but short enough to retain rapid clearance kinetics. It appears in some translational research protocols where moderate duration of action is desirable without committing to the full 54-amino-acid sequence.

Structural modifications beyond native sequences. Such as N-terminal acetylation, C-terminal amidation (standard in kisspeptin-10), or D-amino acid substitutions. Are occasionally used in experimental analogs to enhance stability or selectivity. C-terminal amidation, represented as -NH2, is critical for full bioactivity; the free carboxyl form shows 10–50-fold reduced potency at GPR54. Every kisspeptin peptide synthesized at Real Peptides includes C-terminal amidation as standard unless specified otherwise, ensuring that what arrives at your lab matches the bioactive conformation used in published studies.

Kisspeptin in Reproductive and Metabolic Research Protocols

Kisspeptin research extends across reproductive endocrinology, metabolic disease modeling, puberty timing studies, fertility restoration experiments, and energy balance investigations. The peptide's role as the upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis makes it indispensable for any study examining reproductive hormone secretion, gonadal function, or sex steroid feedback mechanisms.

One of the most replicated findings in kisspeptin research is its ability to reverse hypogonadotropic hypogonadism in animal models and humans with functional GPR54 receptors. Intravenous kisspeptin-10 administration in men with idiopathic hypogonadotropic hypogonadism produced measurable increases in LH, FSH, and testosterone within 90 minutes. A response comparable to GnRH administration. This positions kisspeptin as a research tool for probing GnRH neuron responsiveness, distinguishing hypothalamic from pituitary causes of reproductive dysfunction, and testing downstream steroidogenic capacity.

Metabolic research has identified bidirectional crosstalk between kisspeptin neurons and energy status. Kisspeptin neuron activity is suppressed during negative energy balance (caloric restriction, prolonged exercise, anorexia). A mechanism that links reproductive suppression to metabolic stress. KISS1 neurons in the arcuate nucleus co-express neurokinin B (NKB) and dynorphin, forming the so-called KNDy neuron population that integrates leptin and insulin signaling. Leptin, the adipocyte-derived hormone signaling energy sufficiency, acts on kisspeptin neurons to maintain reproductive axis tone; leptin deficiency or resistance suppresses kisspeptin expression and leads to hypogonadotropic amenorrhea in females and reduced testosterone in males.

Pancreatic beta-cells express GPR54, and kisspeptin has been shown to potentiate glucose-stimulated insulin secretion (GSIS) in rodent islets. An effect independent of its reproductive actions. This observation has spurred investigations into kisspeptin analogs for metabolic disease research, particularly in models of type 2 diabetes where both insulin secretion and reproductive function are impaired. One hypothesis proposes that kisspeptin serves as a metabolic 'gatekeeper,' permitting reproductive investment only when energy reserves are adequate. A concept supported by studies showing kisspeptin neuron suppression in response to fasting, inflammation, and glucocorticoid excess.

Research labs using Kisspeptin 10 for these studies typically administer the peptide via subcutaneous or intravenous injection in animal models or intravenous infusion in human studies. Dosing varies widely depending on species, route, and endpoint: 1–10 nmol/kg in rodents, 0.01–1.0 nmol/kg in primates, and 0.01–4.0 nmol/kg in humans for acute LH stimulation studies. Chronic administration protocols (daily or twice-daily injections over weeks) are used to model sustained kisspeptin tone, investigate desensitization kinetics, and assess long-term metabolic or reproductive outcomes.

Kisspeptin FAQ: Dosing, Reconstitution, and Storage

Kisspeptin peptides are supplied as lyophilized powder and require reconstitution in sterile diluent before use. The most common reconstitution vehicle is bacteriostatic water (0.9% benzyl alcohol in water for injection), which permits multi-dose withdrawal from a single vial over 28 days when refrigerated at 2–8°C. For single-use applications or protocols requiring benzyl alcohol-free conditions, sterile water for injection or phosphate-buffered saline (PBS, pH 7.4) are acceptable alternatives, though these lack antimicrobial preservative and must be used within 24 hours of reconstitution.

Reconstitution procedure: allow the lyophilized vial to reach room temperature (15–20 minutes if stored frozen), then inject the calculated volume of bacteriostatic water slowly down the vial wall. Never directly onto the peptide cake, which can cause aggregation. Gently swirl or roll the vial to dissolve; do not vortex or shake vigorously. Kisspeptin-10 typically dissolves within 30–60 seconds at concentrations up to 1 mg/mL. If cloudiness or particulates persist, discard the vial. This indicates protein denaturation or contamination.

Storage rules: unopened lyophilized kisspeptin should be stored at −20°C for up to 24 months or at 2–8°C for up to 6 months. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days. Avoid freeze-thaw cycles. Aliquot reconstituted peptide into single-use volumes if repeated freezing is necessary, though this is not recommended for peptides with hydrophilic C-terminal sequences like kisspeptin, which are prone to ice crystal-induced aggregation.

Dosing considerations for research protocols: kisspeptin-10 doses in rodent models typically range from 1 to 10 nmol/kg for acute LH stimulation. A 250-gram rat receiving 5 nmol/kg would require 1.25 nmol total dose; if reconstituted at 100 nmol/mL (approximately 0.13 mg/mL for kisspeptin-10, MW ~1300 Da), this equals 12.5 μL injection volume. Easily administered via subcutaneous or intraperitoneal route. Human studies have used doses from 0.01 to 4.0 nmol/kg intravenously; a 70 kg adult at 1.0 nmol/kg receives 70 nmol total, requiring precise infusion pumps for controlled delivery.

Peptide concentration should be optimized for your injection volume constraints and dosing precision. Concentrations below 0.01 mg/mL risk adsorptive loss to vial walls and syringes; concentrations above 5 mg/mL may exceed solubility limits or increase aggregation risk during storage. For most protocols, 0.1–1.0 mg/mL represents the practical working range.

At Real Peptides, every Kisspeptin 10 batch includes a certificate of analysis (CoA) specifying purity (≥98% by HPLC), exact peptide content per vial, and recommended reconstitution volume to achieve target concentrations. This removes guesswork from protocol preparation and ensures reproducibility across experiments.

Kisspeptin FAQ: Type Comparison

All isoforms share the same C-terminal bioactive sequence and demonstrate equivalent receptor potency in vitro. The primary differentiator is pharmacokinetic profile. Kisspeptin-10 offers rapid onset and clearance, kisspeptin-54 provides extended duration, and kisspeptin-13 sits between them. Selection depends on study design: pulsatile administration experiments favor kisspeptin-10, while continuous infusion or chronic injection protocols often favor kisspeptin-54 to minimize dosing frequency.

What If: Kisspeptin FAQ Scenarios

What If Reconstituted Kisspeptin Is Left at Room Temperature Overnight?

Discard it. Peptides containing hydrophilic residues like serine, asparagine, and arginine (all present in kisspeptin's C-terminus) are highly susceptible to bacterial contamination and chemical degradation at temperatures above 8°C. Even if bacteriostatic water was used, 12–24 hours at room temperature increases the risk of peptidase activity from trace contaminants, oxidation of the tryptophan residue at position 3 (kisspeptin-10 numbering), and partial aggregation. The cost of replacing the vial is trivial compared to the risk of invalid results from degraded peptide. Maintaining strict 2–8°C storage after reconstitution is non-negotiable.

What If LH Response to Kisspeptin Is Blunted or Absent?

First, verify peptide integrity: check the CoA for purity, confirm proper reconstitution (no cloudiness or particulates), and ensure the vial was stored correctly. If the peptide is intact, a blunted LH response suggests either GPR54 receptor desensitization (if prior kisspeptin doses were administered within 6–12 hours), pituitary gonadotroph suppression (from exogenous sex steroids or GnRH analogs), or a primary pituitary defect. In rodent models, prior estradiol or testosterone administration can suppress gonadotroph responsiveness independent of kisspeptin signaling. In humans, use of hormonal contraceptives, anabolic steroids, or selective androgen receptor modulators (SARMs) within the prior 4–8 weeks can blunt LH response. A wash-out period of at least two weeks is recommended before kisspeptin challenge studies in models with prior hormonal manipulation.

What If the Research Protocol Requires Daily Kisspeptin Administration for Weeks?

Expect receptor desensitization unless dosing is pulsatile or intermittent. Continuous kisspeptin exposure downregulates GPR54 surface expression on GnRH neurons, reducing LH pulse amplitude after 48–72 hours of sustained stimulation. Published protocols using chronic kisspeptin administration either use once-daily bolus injections (allowing 23 hours between doses for receptor resensitization) or pulsatile infusion via programmable pumps (10–15 minute pulses every 60–90 minutes, mimicking endogenous kisspeptin neuron firing patterns). Continuous infusion models are used deliberately to study desensitization kinetics or model downregulated states, but are not appropriate for protocols expecting sustained LH elevation. If your study design requires weeks of daily kisspeptin without desensitization, once-daily subcutaneous injection (preferably at the same circadian time each day) is the standard approach.

What If the Study Involves Female Rodents — Does Estrous Cycle Stage Matter?

Absolutely. Kisspeptin neuron activity and GnRH/LH responsiveness vary across the estrous cycle due to estradiol feedback. During proestrus (the preovulatory phase), estradiol exerts positive feedback on AVPV kisspeptin neurons, dramatically increasing kisspeptin expression and GnRH/LH secretion. This is the neurobiological trigger for the LH surge that induces ovulation. Administering exogenous kisspeptin during proestrus produces exaggerated LH responses compared to diestrus or metestrus. If your protocol aims to measure baseline kisspeptin sensitivity, use female rodents in diestrus (low estradiol, low progesterone) or ovariectomized models with controlled hormone replacement. If modeling the LH surge mechanism, proestrus is the appropriate stage. Failure to control for cycle stage introduces 3–5-fold variability in LH response and is a common source of irreproducibility in kisspeptin studies.

The Direct Truth About Kisspeptin FAQ

Here's the honest answer: most kisspeptin FAQ content online is written for patients asking about 'kisspeptin therapy' for fertility or libido. Not for researchers running controlled experiments. That audience mismatch means most FAQs skip the details that matter in a lab: receptor pharmacology, isoform selection rationale, species-specific dosing, reconstitution vehicle choice, and how to troubleshoot blunted responses. If you're designing a study, you don't need to know that 'kisspeptin is involved in puberty'. You need to know that GPR54 couples through Gαq/11, that desensitization occurs within 48 hours of continuous exposure, and that kisspeptin-10's 4-minute half-life requires precise timing between administration and blood sampling.

The bottom line: kisspeptin is one of the most reproducible tools in reproductive neuroendocrinology if you control for the variables that matter. Peptide purity, receptor state, hormonal background, and pharmacokinetic matching of isoform to study design. It's also one of the easiest to misuse if you treat it like a generic 'hormone booster' without understanding the signaling cascade it activates. The research-grade Kisspeptin 10 we supply is synthesized to match the bioactive C-terminal sequence used in every major kisspeptin study published since 2005. Exact sequence, C-terminal amidation, ≥98% purity by HPLC. That specificity is what separates reproducible results from confounded experiments.

Most peptide suppliers list kisspeptin in a catalog with no mechanistic context, no isoform rationale, and no protocol guidance. We built Real Peptides to close that gap. Every compound page includes mechanism-of-action summaries, receptor targets, typical dose ranges by species, and storage recommendations based on peptide structure. If your study depends on precise neuroendocrine signaling, the peptide you use should come with the technical depth to support that precision.

If kisspeptin doesn't produce the expected LH response in your model, the first question isn't 'does kisspeptin work?'. It's 'what variable in my protocol differs from the conditions under which kisspeptin's mechanism was characterized?' That variable is almost always receptor state (desensitized from prior dosing or suppressed by exogenous hormones), peptide handling (storage temperature excursion or reconstitution error), or timing (blood sampling outside the 30–90 minute LH response window). Kisspeptin's mechanism is one of the most validated in reproductive biology. But validation requires experimental rigor, and rigor requires starting with a peptide that matches published reference standards.",
"faqs": [
{
"question": "How does kisspeptin activate the reproductive axis at the molecular level?",
"answer": "Kisspeptin binds to GPR54 (KISS1R), a G-protein-coupled receptor on GnRH neurons, activating Gαq/11 signaling. This triggers phospholipase C (PLC) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 releases intracellular calcium stores, causing GnRH vesicle exocytosis, while DAG activates protein kinase C (PKC) to potentiate the response. The result is rapid GnRH secretion within seconds, followed by downstream LH and FSH release from the pituitary within 15–30 minutes."
},
{
"question": "Can kisspeptin be used in ovariectomized or castrated animal models?",
"answer": "Yes. Kisspeptin retains full activity in gonadectomized models and is frequently used to study GnRH neuron responsiveness independent of sex steroid feedback. Ovariectomized females and castrated males show exaggerated LH responses to kisspeptin due to removal of negative feedback from estradiol or testosterone. These models are standard for isolating central (hypothalamic) effects of kisspeptin from peripheral (gonadal) confounders. Hormone replacement (estradiol, testosterone, or progesterone) can be added back in controlled doses to model specific feedback states."
},
{
"question": "What is the cost difference between kisspeptin-10 and kisspeptin-54 for research?",
"answer": "Kisspeptin-10 is significantly less expensive to synthesize due to its shorter sequence (10 amino acids vs 54), resulting in lower per-milligram cost. Typically 40–60% less than kisspeptin-54 for equivalent molar amounts. Since both isoforms demonstrate equivalent receptor potency (EC50 ~1–10 nM), most labs use kisspeptin-10 unless the study specifically requires prolonged plasma half-life. For dose-response studies, receptor binding assays, or acute stimulation experiments, kisspeptin-10 offers identical scientific utility at lower cost."
},
{
"question": "How do you distinguish hypothalamic vs pituitary causes of reproductive dysfunction using kisspeptin?",
"answer": "Administer kisspeptin and measure LH response. A normal LH increase indicates intact pituitary gonadotrophs and suggests hypothalamic GnRH deficiency (kisspeptin or GnRH neuron dysfunction). Blunted or absent LH response despite kisspeptin administration suggests primary pituitary failure or gonadotroph suppression. This diagnostic logic is used in human studies of idiopathic hypogonadotropic hypogonadism and in animal models to localize lesions within the HPG axis. Following kisspeptin with exogenous GnRH administration further isolates the defect: if GnRH produces LH but kisspeptin does not, the lesion is at or above the GnRH neuron."
},
{
"question": "Does kisspeptin cross the blood-brain barrier when administered peripherally?",
"answer": "No. Kisspeptin is a hydrophilic peptide and does not cross the intact blood-brain barrier in significant amounts. Peripheral (intravenous or subcutaneous) kisspeptin administration in humans and animals acts on GnRH neurons in the median eminence, a circumventricular organ outside the blood-brain barrier where GnRH neuron terminals are exposed to circulating factors. For central nervous system studies requiring direct brain kisspeptin exposure, intracerebroventricular (ICV) or direct hypothalamic microinjection is required."
},
{
"question": "What is the difference between kisspeptin and GnRH for research applications?",
"answer": "Kisspeptin acts upstream of GnRH, stimulating GnRH neurons to secrete GnRH, which then triggers pituitary LH/FSH release. Exogenous GnRH bypasses the hypothalamus entirely and acts directly on pituitary gonadotrophs. Kisspeptin is used to study hypothalamic control, GnRH neuron responsiveness, and metabolic-reproductive integration; GnRH is used to study pituitary function, gonadotroph sensitivity, and gonadal steroidogenic capacity. In diagnostic or experimental contexts, comparing kisspeptin vs GnRH responses helps localize defects to hypothalamic vs pituitary origins."
},
{
"question": "Can kisspeptin be administered orally in research models?",
"answer": "No. Kisspeptin is a peptide and undergoes complete proteolytic degradation in the gastrointestinal tract, resulting in zero oral bioavailability. All published kisspeptin research uses parenteral routes: intravenous, subcutaneous, intraperitoneal (in rodents), or intracerebroventricular for CNS studies. Oral kisspeptin formulations or 'kisspeptin supplements' marketed to consumers have no biological plausibility and are not used in legitimate research protocols."
},
{
"question": "How long does GPR54 receptor desensitization last after continuous kisspeptin exposure?",
"answer": "GPR54 desensitization begins within 48–72 hours of continuous kisspeptin exposure and can persist for 5–7 days after cessation, depending on species and dose. In rodent studies using continuous infusion, LH pulse amplitude declines by 50–70% after three days of sustained kisspeptin exposure. Recovery of full receptor responsiveness requires at least 48–96 hours washout. This is why chronic kisspeptin protocols use once-daily bolus dosing (allowing 23 hours between exposures) rather than continuous infusion, unless the study explicitly investigates desensitization kinetics."
},
{
"question": "What quality control measures confirm kisspeptin peptide purity and sequence accuracy?",
"answer": "High-performance liquid chromatography (HPLC) measures peptide purity by separating the target peptide from truncated sequences, deletion analogs, and impurities. Purity ≥98% is standard for research-grade material. Mass spectrometry (MS) confirms exact molecular weight, verifying correct amino acid sequence and post-translational modifications like C-terminal amidation. Amino acid analysis (AAA) quantifies each residue to confirm sequence composition. At Real Peptides, every batch includes a certificate of analysis (CoA) with HPLC chromatogram, MS spectrum, and peptide content per vial."
},
{
"question": "Why is C-terminal amidation critical for kisspeptin bioactivity?",
"answer": "The C-terminal phenylalanine residue in kisspeptin (position 54 in kisspeptin-54, position 10 in kisspeptin-10) must be amidated (-NH2) for full receptor binding and activation. The free carboxyl form (-COOH) shows 10–50-fold reduced potency at GPR54 due to altered binding geometry and charge distribution at the receptor interface. C-terminal amidation is a standard post-translational modification in neuropeptides and is included in all research-grade kisspeptin synthesis. Peptides supplied without explicit amidation notation may contain the less active carboxyl form."
},
{
"question": "What is the relationship between kisspeptin and leptin in metabolic research?",
"answer": "Leptin, the adipocyte hormone signaling energy sufficiency, directly stimulates kisspeptin neurons in the arcuate nucleus via leptin receptors (LepR) expressed on KISS1 neurons. Leptin deficiency or resistance suppresses kisspeptin expression, reducing GnRH/LH secretion and causing hypogonadotropic hypogonadism. This is the mechanism linking starvation, anorexia, or excessive exercise to reproductive suppression. Kisspeptin administration can partially restore LH secretion in leptin-deficient models, demonstrating that kisspeptin acts downstream of leptin in the metabolic-reproductive signaling cascade. This relationship is central to research on hypothalamic amenorrhea, polycystic ovary syndrome (PCOS), and obesity-related reproductive dysfunction."
},
{
"question": "Can kisspeptin be used to study puberty timing in animal models?",
"answer": "Yes. Kisspeptin is the primary trigger for puberty onset across mammalian species. Pre-pubertal increases in kisspeptin neuron activity (particularly in the AVPV) initiate the rise in GnRH secretion that drives gonadarche and the development of secondary sex characteristics. Experimental kisspeptin administration in juvenile rodents can advance puberty timing, while GPR54 antagonists or KISS1 gene knockdown delay or prevent puberty. These models are used to study environmental, nutritional, and genetic factors regulating puberty onset, including the role of body fat, leptin signaling, and metabolic status in reproductive maturation."
}
]
}